1. Home
  2. |Insights
  3. |'Rise' of the Machines: FAA Publishes Plans for Unmanned Aircraft Systems Operations

'Rise' of the Machines: FAA Publishes Plans for Unmanned Aircraft Systems Operations

Client Alert | less than 1 min read | 11.07.13

On November 7, the FAA released its first annual Roadmap outlining efforts to integrate unmanned aircraft systems (UAS) into the national airspace system safely, including the policies, regulations, technologies, and procedures to make civil and commercial UAS operations a reality. The Roadmap, released along with the Joint Planning and Development Office's Comprehesive Plan to accelerate UAS integration, and FAA's final Privacy Plan requirements for the six UAS Test Sites that will be selected later this year (discussed here) are good news for aerospace manufacturers and other industries interested in UAS development, including agriculture, oil and gas, and law enforcement.p>

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights